LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・Blueprint Medicines Corp

Blueprint Medicines Corp

Затворен

СекторЗдравеопазване

101.56 2.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

97.61

Максимум

101.99

Ключови измерители
By Trading Economics
Приходи	50M 496K
Продажби	3M 149M
EPS	-0.294
Марж на печалбата	0.332
Служители	682
EBITDA	-14M -41M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+28.12% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	763M 6.5B
Предишно отваряне	99.05
Предишно затваряне	101.56

Настроения в новините

By Acuity

32%

68%

96 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

87.66 / 99.25 Подкрепа & съпротива

Blueprint Medicines Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2025 г., 22:52 ч. UTC

Печалби

Значими двигатели на пазара

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15.05.2025 г., 20:37 ч. UTC

Топ новини

Печалби

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16.05.2025 г., 00:00 ч. UTC

Пазарно говорене

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15.05.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.05.2025 г., 23:14 ч. UTC

Топ новини

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15.05.2025 г., 22:46 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15.05.2025 г., 21:58 ч. UTC

Печалби

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15.05.2025 г., 21:24 ч. UTC

Печалби

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15.05.2025 г., 20:56 ч. UTC

Пазарно говорене

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Пазарно говорене

Печалби

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15.05.2025 г., 20:54 ч. UTC

Печалби

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15.05.2025 г., 20:51 ч. UTC

Печалби

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.05.2025 г., 20:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15.05.2025 г., 20:50 ч. UTC

Печалби

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15.05.2025 г., 20:47 ч. UTC

Печалби

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15.05.2025 г., 20:37 ч. UTC

Печалби

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15.05.2025 г., 20:26 ч. UTC

Топ новини

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15.05.2025 г., 20:25 ч. UTC

Печалби

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Blueprint Medicines Corp Прогноза

Ценова цел

By TipRanks

28.12% нагоре

12-месечна прогноза

Среден 127.47 USD 28.12%

Висок 155 USD

Нисък 93 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Blueprint Medicines Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на Blueprint Medicines Corp през последните 3 месеца.

Техническа оценка

By Trading Central

87.66 / 99.25Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

96 / 382 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.